ArticleBlood2011
Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 159 citations in OpenAlex.
- Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.The Journal of clinical investigation · 2014Trial
- Safety and Efficacy of Mosunetuzumab: Experience in the Hospital Cardinale Giovanni Panico.Antibodies (Basel, Switzerland) · 2026Article
- Paraneoplastic Erythroderma: An Unprecedented Initial Manifestation of In Situ Follicular Neoplasia.Cureus · 2025Article
- Splenosis involved by in situ follicular B-cell neoplasm.Virchows Archiv : an international journal of pathology · 2025Article
- A rare case of in situ follicular B-cell neoplasm involving sebaceous lymphadenoma.Journal of hematopathology · 2025Article
- Evolution of Lymphoma Diagnosis in the Era of Personalized Medicine: A Marriage of Pathology and Genomics for Clinical Practice.The American journal of pathology · 2023Review
- Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors.Cancer discovery · 2023Article
- In situ follicular neoplasm discovered as an enlarging pulmonary nodule complicated by pulmonary aspergillosis.Thoracic cancer · 2023Article
- Review
- Follicular lymphoma and marginal zone lymphoma: how many diseases?Virchows Archiv : an international journal of pathology · 2023Review
- Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics.Journal of clinical and experimental hematopathology : JCEH · 2023Review
- Follicular lymphoma: updates for pathologists.Journal of pathology and translational medicine · 2022Review
- [Genetic evolution of in situ follicular neoplasia to t(14;18)-positive aggressive B-cell lymphoma].Der Pathologe · 2021Review
- Genetic evolution ofHaematologica · 2021Article
- Lack of activation-induced cytidine deaminase expression in in situ follicular neoplasia.Haematologica · 2021Article
- Prevalence of Lymphoid Neoplasia in a Retrospective Analysis of Warthin Tumor: A Single Institution Experience.Head and neck pathology · 2020Article
- The broad landscape of follicular lymphoma: Part I.Pathologica · 2020Review
- B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making.Frontiers in oncology · 2020Review
- Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.Hematology/oncology clinics of North America · 2019Review
- [Revised version of the 4th edition of the WHO classification of malignant lymphomas : What is new?]Der Pathologe · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Follicular lymphoma in situ (FLIS) was first described nearly a decade ago, but its clinical significance remains uncertain. We reevaluated our original series and more recently diagnosed cases to develop criteria for the distinction of FLIS from partial involvement by follicular lymphoma (PFL). A total of 34 cases of FLIS were identified, most often as an incidental finding in a reactive lymph node. Six of 34 patients had prior or concurrent FL, and 5 of 34 had FLIS composite with another lymphoma. Of patients with negative staging at diagnosis and available follow-up (21 patients), only one (5%) developed FL (follow-up: median, 41 months; range, 10-118 months). Follow-up was not available in 2 cases. Fluorescence in situ hybridization for BCL2 gene rearrangement was positive in all 17 cases tested. PFL patients were more likely to develop FL, diagnosed in 9 of 17 (53%) who were untreated. Six patients with PFL were treated with local radiation therapy (4) or rituximab (2) and remained with no evidence of disease. FLIS can be reliably distinguished from PFL and has a very low rate of progression to clinically significant FL. FLIS may represent the tissue counterpart of circulating t(14;18)-positive B cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.